{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T13:11:13Z","timestamp":1765285873212,"version":"3.46.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-27359-1","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:47:58Z","timestamp":1765280878000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of citrate dialysate on middle molecular weight uremic toxin adsorption and removal in high-flux and MCO dialysis membranes"],"prefix":"10.1038","volume":"15","author":[{"given":"Miquel","family":"Gomez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Rodriguez-Espinosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Jesus","family":"Broseta Monzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Arias-Guillen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nestor","family":"Fontser\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lida","family":"Rodas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Maduell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"27359_CR1","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1525-1594.1986.tb02554.x","volume":"10","author":"E Klein","year":"1986","unstructured":"Klein, E., Ward, R. A. & Harding, G. B. Calcium carbonate precipitation in bicarbonate Hemodialysis. Artif. Organs. 10, 248\u2013250 (1986).","journal-title":"Artif. Organs"},{"key":"27359_CR2","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.kint.2016.01.010","volume":"89","author":"C Basile","year":"2016","unstructured":"Basile, C., Rossi, L. & Lomonte, C. The choice of dialysate bicarbonate: do different concentrations make a difference? Kidney Int. 89, 1008\u20131015 (2016).","journal-title":"Kidney Int."},{"key":"27359_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/1744-9987.12180","volume":"19","author":"JJ S\u00e1nchez-Canel","year":"2015","unstructured":"S\u00e1nchez-Canel, J. J., Hern\u00e1ndez\u2010Jaras, J. & Pons\u2010Prades, R. A. Randomized controlled study on the effects of acetate\u2010free biofiltration on organic anions and acid\u2010base balance in Hemodialysis patients. Ther. Apher Dial. 19, 63\u201372 (2015).","journal-title":"Ther. Apher Dial"},{"key":"27359_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1053\/ajkd.1998.v32.pm9669432","volume":"32","author":"M Noris","year":"1998","unstructured":"Noris, M. et al. Effect of acetate, bicarbonate dialysis, and acetate-free biofiltration on nitric oxide synthesis: implications for dialysis hypotension. Am. J. Kidney Dis. 32, 115\u2013124 (1998).","journal-title":"Am. J. Kidney Dis."},{"key":"27359_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/01.mat.0000189725.93808.58","volume":"52","author":"NM Selby","year":"2006","unstructured":"Selby, N. M., Fluck, R. J., Taal, M. W. & McIntyre, C. W. Effects of acetate-free double-chamber hemodiafiltration and standard dialysis on systemic hemodynamics and troponin T levels. ASAIO J. 52, 62\u201369 (2006).","journal-title":"ASAIO J."},{"key":"27359_CR6","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/j.1744-9987.2011.00976.x","volume":"15","author":"S Daimon","year":"2011","unstructured":"Daimon, S., Dan, K. & Kawano, M. Comparison of Acetate-Free citrate Hemodialysis and bicarbonate Hemodialysis regarding the effect of Intra\u2010Dialysis hypotension and Post\u2010Dialysis malaise. Ther. Apher Dial. 15, 460\u2013465 (2011).","journal-title":"Ther. Apher Dial"},{"key":"27359_CR7","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1161\/01.CIR.0000041254.30637.34","volume":"106","author":"FS Apple","year":"2002","unstructured":"Apple, F. S., Murakami, M. M., Pearce, L. A. & Herzog, C. A. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 106, 2941\u20132945 (2002).","journal-title":"Circulation"},{"key":"27359_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000337476","volume":"2","author":"MY Zuidema","year":"2012","unstructured":"Zuidema, M. Y. & Dellsperger, K. C. Myocardial stunning with hemodialysis: clinical challenges of the cardiorenal patient. Cardiorenal Med. 2, 125\u2013133 (2012).","journal-title":"Cardiorenal Med."},{"key":"27359_CR9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s10047-010-0551-7","volume":"14","author":"K Matsuyama","year":"2011","unstructured":"Matsuyama, K., Tomo, T. & Kadota, J. Acetate-free blood purification can impact improved nutritional status in hemodialysis patients. J. Artif. Organs. 14, 112\u2013119 (2011).","journal-title":"J. Artif. Organs"},{"key":"27359_CR10","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1093\/ndt\/gfy134","volume":"33","author":"G Lorenz","year":"2018","unstructured":"Lorenz, G. et al. Acetate-free, citrate-acidified bicarbonate dialysis improves serum calcification propensity\u2014a preliminary study. Nephrol. Dial Transpl. 33, 2043\u20132051 (2018).","journal-title":"Nephrol. Dial Transpl."},{"key":"27359_CR11","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1159\/000513419","volume":"50","author":"JJ Broseta","year":"2021","unstructured":"Broseta, J. J. et al. Improvements in inflammation and calcium balance of citrate versus acetate as dialysate buffer in maintenance hemodialysis: a unicentric, cross-over, prospective study. Blood Purif. 50, 914\u2013920 (2021).","journal-title":"Blood Purif."},{"key":"27359_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/1479164111424297","volume":"9","author":"A Bryland","year":"2012","unstructured":"Bryland, A., Wieslander, A., Carlsson, O., Hellmark, T. & Godaly, G. Citrate treatment reduces endothelial death and inflammation under hyperglycaemic conditions. Diabetes Vasc Dis. Res. 9, 42\u201351 (2012).","journal-title":"Diabetes Vasc Dis. Res."},{"key":"27359_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3390\/antiox9040319","volume":"9","author":"C Vida","year":"2020","unstructured":"Vida, C. et al. Increasing the magnesium concentration in various dialysate solutions differentially modulates oxidative stress in a human monocyte cell line. Antioxidants 9, 319 (2020).","journal-title":"Antioxidants"},{"key":"27359_CR14","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s40620-020-00943-6","volume":"34","author":"F Pizzarelli","year":"2021","unstructured":"Pizzarelli, F. et al. Citrate high volume on-line hemodiafiltration modulates serum Interleukin-6 and Klotho levels: the multicenter randomized controlled study hephaestus. J. Nephrol. 34, 1701\u20131710 (2021).","journal-title":"J. Nephrol."},{"key":"27359_CR15","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1093\/ndt\/gfk093","volume":"21","author":"F Pizzarelli","year":"2006","unstructured":"Pizzarelli, F., Cerrai, T., Dattolo, P. & Ferro, G. On-line haemodiafiltration with and without acetate. Nephrol. Dial Transpl. 21, 1648\u20131651 (2006).","journal-title":"Nephrol. Dial Transpl."},{"key":"27359_CR16","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1093\/ndt\/gfaa168","volume":"35","author":"C Couchoud","year":"2020","unstructured":"Couchoud, C. et al. Impact of the dialysate acid component on haemodialysis mortality rates. Nephrol. Dial Transpl. 35, 1244\u20131249 (2020).","journal-title":"Nephrol. Dial Transpl."},{"key":"27359_CR17","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1093\/ckj\/sfad069","volume":"16","author":"P Thanapongsatorn","year":"2023","unstructured":"Thanapongsatorn, P. et al. Standard versus no post-filter ionized calcium monitoring in regional citrate anticoagulation for continuous renal replacement therapy (NPC trial). Clin. Kidney J. 16, 1469\u20131479 (2023).","journal-title":"Clin. Kidney J."},{"key":"27359_CR18","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00134-024-07531-3","volume":"50","author":"PM Honor\u00e9","year":"2024","unstructured":"Honor\u00e9, P. M., Rimmel\u00e9, T. & Joannes-Boyau, O. Citrate anticoagulation for continuous renal replacement therapy. Intensive Care Med. 50, 1553\u20131556 (2024).","journal-title":"Intensive Care Med."},{"key":"27359_CR19","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1093\/ndt\/gfq225","volume":"25","author":"M Kreuzer","year":"2010","unstructured":"Kreuzer, M. et al. Regional citrate anticoagulation is safe in intermittent high-flux haemodialysis treatment of children and adolescents with an increased risk of bleeding. Nephrol. Dial Transpl. 25, 3337\u20133342 (2010).","journal-title":"Nephrol. Dial Transpl."},{"key":"27359_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-019-1661-y","volume":"20","author":"T Lin","year":"2019","unstructured":"Lin, T. et al. Modified regional citrate anticoagulation is optimal for Hemodialysis in patients at high risk of bleeding: a prospective randomized study of three anticoagulation strategies. BMC Nephrol. 20, 1\u201314 (2019).","journal-title":"BMC Nephrol."},{"key":"27359_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40620-021-00991-6","volume":"35","author":"D Marcelli","year":"2022","unstructured":"Marcelli, D. & Basile, C. Has time come to replace the residual acetate with citrate in the dialysis fluid? J. Nephrol. 35, 87\u201390 (2022).","journal-title":"J. Nephrol."},{"key":"27359_CR22","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s11064-016-2159-7","volume":"42","author":"N Westergaard","year":"2017","unstructured":"Westergaard, N., Waagepetersen, H. S., Belhage, B. & Schousboe, A. Citrate, a ubiquitous key metabolite with regulatory function in the CNS. Neurochem Res. 42, 1583\u20131588 (2017).","journal-title":"Neurochem Res."},{"key":"27359_CR23","doi-asserted-by":"publisher","unstructured":"Glusker, J. P. Structural aspects of citrate biochemistry. in Current Topics in Cellular Regulation 169\u2013184 (ACADEMIC, INC). https:\/\/doi.org\/10.1016\/B978-0-12-152833-1.50015-0. (1992).","DOI":"10.1016\/B978-0-12-152833-1.50015-0"},{"key":"27359_CR24","doi-asserted-by":"crossref","unstructured":"Panichi, V. et al. Post-dilution on line haemodiafiltration with citrate dialysate: first clinical experience in chronic dialysis patients. ScientificWorldJournal 703612 2013 (2013).","DOI":"10.1155\/2013\/703612"},{"key":"27359_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2369-10-7","volume":"10","author":"L Gabutti","year":"2009","unstructured":"Gabutti, L., Lucchini, B., Marone, C., Alberio, L. & Burnier, M. Citrate- vs. acetate-based dialysate in bicarbonate haemodialysis: consequences on haemodynamics, coagulation, acid-base status, and electrolytes. BMC Nephrol. 10, 7 (2009).","journal-title":"BMC Nephrol."},{"key":"27359_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s41100-024-00553-z","volume":"10","author":"K Okada","year":"2024","unstructured":"Okada, K. et al. Acetate-containing bicarbonate dialysate increases all-cause mortality more than acetate-free bicarbonate dialysate containing citrate in hemodialysis patients. Ren. Replace. Ther. 10, 44 (2024).","journal-title":"Ren. Replace. Ther."},{"key":"27359_CR27","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/aor.13506","volume":"43","author":"J Mares","year":"2019","unstructured":"Mares, J., Tuma, Z., Moravec, J., Pavlina, R. & Matejovic, M. Proteins adsorbed to a polysulfone hemodialysis membrane under heparin and citrate anticoagulation regimens. Artif. Organs. 43, 1092\u20131103 (2019).","journal-title":"Artif. Organs"},{"key":"27359_CR28","doi-asserted-by":"crossref","unstructured":"Huang, Z., Gao, D., Letteri, J. J. & Clark, W. R. Innovation in the treatment of uremia: proceedings from the cleveland clinic workshop: blood\u2013membrane interactions during dialysis. Semin. Dial. 22, 623\u2013628 (2009).","DOI":"10.1111\/j.1525-139X.2009.00658.x"},{"key":"27359_CR29","doi-asserted-by":"publisher","first-page":"iii41","DOI":"10.1093\/ndt\/gfy202","volume":"33","author":"C Ronco","year":"2018","unstructured":"Ronco, C. et al. Expanded haemodialysis: from operational mechanism to clinical results. Nephrol. Dial Transpl. 33, iii41\u2013iii47 (2018).","journal-title":"Nephrol. Dial Transpl."},{"key":"27359_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-022-02960-y","volume":"23","author":"MM Vre\u010dko","year":"2022","unstructured":"Vre\u010dko, M. M., Pajek, J. & Buturovi\u0107-Ponikvar, J. Use of regional citrate anticoagulation with medium cut-off membrane: pilot report. BMC Nephrol. 23, 1\u20135 (2022).","journal-title":"BMC Nephrol."},{"key":"27359_CR31","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.nefro.2021.06.006","volume":"42","author":"P de Sequera","year":"2022","unstructured":"de Sequera, P. et al. Advantages of the use of citrate over acetate as a stabilizer in hemodialysis fluid: a randomized ABC-treat study. Nefrologia 42, 327\u2013337 (2022).","journal-title":"Nefrologia"},{"key":"27359_CR32","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3390\/toxins16100426","volume":"16","author":"D Rodr\u00edguez-Espinosa","year":"2024","unstructured":"Rodr\u00edguez-Espinosa, D. et al. Comparative effects of Acetate- and Citrate-Based dialysates on Dialysis dose and Protein-Bound uremic toxins in hemodiafiltration patients: exploring the impact of calcium and magnesium concentrations. Toxins (Basel). 16, 426 (2024).","journal-title":"Toxins (Basel)"},{"key":"27359_CR33","doi-asserted-by":"publisher","first-page":"2398709","DOI":"10.1080\/0886022X.2024.2398709","volume":"46","author":"JY Lee","year":"2024","unstructured":"Lee, J. Y. et al. Switching from acetate to citrate dialysate in a central concentrate delivery system for high-volume online hemodiafiltration: a retrospective cohort study. Ren. Fail. 46, 2398709 (2024).","journal-title":"Ren. Fail."},{"key":"27359_CR34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1159\/000524644","volume":"52","author":"F Maduell","year":"2023","unstructured":"Maduell, F. et al. Efficacy and safety of the medium cut-off Elisio HX dialyzer. Blood Purif. 52, 68\u201374 (2023).","journal-title":"Blood Purif."},{"key":"27359_CR35","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40620-015-0207-z","volume":"29","author":"C Bourguignon","year":"2016","unstructured":"Bourguignon, C. et al. Hemodiafiltration improves free light chain removal and normalizes \u03ba\/\u03bb ratio in Hemodialysis patients. J. Nephrol. 29, 251\u2013257 (2016).","journal-title":"J. Nephrol."},{"key":"27359_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2023.1193504","volume":"13","author":"CW Schaaf","year":"2023","unstructured":"Schaaf, C. W. et al. Extracorporeal light-chain elimination in myeloma with simple medium cutoff membrane hemodialysis: a retrospective cohort study. Front. Oncol. 13, 1\u20139 (2023).","journal-title":"Front. Oncol."},{"key":"27359_CR37","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s41581-018-0002-x","volume":"14","author":"C Ronco","year":"2018","unstructured":"Ronco, C. & Clark, W. R. Haemodialysis membranes. Nat. Rev. Nephrol. 14, 394\u2013410 (2018).","journal-title":"Nat. Rev. Nephrol."},{"key":"27359_CR38","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1039\/C5MB00058K","volume":"11","author":"L Pieroni","year":"2015","unstructured":"Pieroni, L. et al. Biocompatibility assessment of haemodialysis membrane materials by proteomic investigations. Mol. Biosyst. 11, 1633\u20131643 (2015).","journal-title":"Mol. Biosyst"},{"key":"27359_CR39","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1046\/j.1525-1594.1998.06083.x","volume":"22","author":"A Fujimori","year":"1998","unstructured":"Fujimori, A., Naito, H. & Miyazaki, T. Adsorption of Complement, Cytokines, and proteins by different Dialysis membrane materials: evaluation by confocal laser scanning fluorescence microscopy. Artif. Organs. 22, 1014\u20131017 (1998).","journal-title":"Artif. Organs"},{"key":"27359_CR40","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/ndt\/18.2.252","volume":"18","author":"J Chanard","year":"2003","unstructured":"Chanard, J., Lavaud, S., Randoux, C. & Rieu, P. New insights in dialysis membrane biocompatibility: relevance of adsorption properties and heparin binding. Nephrol. Dial Transpl. 18, 252\u2013257 (2003).","journal-title":"Nephrol. Dial Transpl."},{"key":"27359_CR41","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/ki.2009.138","volume":"76","author":"J Mares","year":"2009","unstructured":"Mares, J., Thongboonkerd, V., Tuma, Z., Moravec, J. & Matejovic, M. Specific adsorption of some complement activation proteins to polysulfone dialysis membranes during Hemodialysis. Kidney Int. 76, 404\u2013413 (2009).","journal-title":"Kidney Int."},{"key":"27359_CR42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000514936","volume":"51","author":"M Gomez","year":"2022","unstructured":"Gomez, M. et al. Distinct solute removal patterns by similar surface high-flux membranes in haemodiafiltration: the adsorption point of view. Blood Purif. 51, 38\u201346 (2022).","journal-title":"Blood Purif."},{"key":"27359_CR43","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10157-022-02182-4","volume":"26","author":"Y Sakaguchi","year":"2022","unstructured":"Sakaguchi, Y. The emerging role of magnesium in CKD. Clin. Exp. Nephrol. 26, 379\u2013384 (2022).","journal-title":"Clin. Exp. Nephrol."},{"key":"27359_CR44","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1053\/j.ajkd.2009.12.016","volume":"55","author":"K Matsushita","year":"2010","unstructured":"Matsushita, K., Selvin, E., Bash, L. D., Astor, B. C. & Coresh, J. Risk implications of the new CKD epidemiology collaboration (CKD-EPI) equation compared with the MDRD study equation for estimated GFR: the atherosclerosis risk in communities (ARIC) study. Am. J. Kidney Dis. 55, 648\u2013659 (2010).","journal-title":"Am. J. Kidney Dis."},{"key":"27359_CR45","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Espinosa, D. et al. Citrate dialysate with and without magnesium supplementation in hemodiafiltration: a comparative study versus acetate. Int J. Mol. Sci 25 (2024).","DOI":"10.20944\/preprints202407.0304.v1"},{"key":"27359_CR46","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/ndt\/gfv347","volume":"31","author":"M Schmitz","year":"2016","unstructured":"Schmitz, M. et al. Effects of citrate dialysate in chronic dialysis: a multicentre randomized crossover study. Nephrol. Dial Transpl. 31, 1327\u20131334 (2016).","journal-title":"Nephrol. Dial Transpl."},{"key":"27359_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-024-03659-y","volume":"25","author":"T Dimski","year":"2024","unstructured":"Dimski, T., Brandenburger, T., Vollmer, C. & Kindgen-Milles, D. A safe and effective protocol for postdilution hemofiltration with regional citrate anticoagulation. BMC Nephrol. 25, 1\u201311 (2024).","journal-title":"BMC Nephrol."},{"key":"27359_CR48","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1053\/j.ajkd.2004.12.002","volume":"45","author":"R Apsner","year":"2005","unstructured":"Apsner, R., Buchmayer, H., Gruber, D. & Sunder-Plassmann, G. Citrate for long-term hemodialysis: prospective study of 1,009 consecutive high-flux treatments in 59 patients. Am. J. Kidney Dis. 45, 557\u2013564 (2005).","journal-title":"Am. J. Kidney Dis."},{"key":"27359_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0225824","volume":"14","author":"KJ ter Meulen","year":"2019","unstructured":"ter Meulen, K. J. et al. Citric-acid dialysate improves the calcification propensity of Hemodialysis patients: A multicenter prospective randomized crossover trial. PLoS One. 14, 1\u201316 (2019).","journal-title":"PLoS One"},{"key":"27359_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-47934-7","volume":"9","author":"R Villa-Bellosta","year":"2019","unstructured":"Villa-Bellosta, R., Hern\u00e1ndez-Mart\u00ednez, E., M\u00e9rida-Herrero, E. & Gonz\u00e1lez-Parra, E. Impact of acetate- or citrate-acidified bicarbonate dialysate on ex vivo aorta wall calcification. Sci. Rep. 9, 1\u20137 (2019).","journal-title":"Sci. Rep."},{"key":"27359_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-47815-z","volume":"9","author":"S Singh","year":"2019","unstructured":"Singh, S. et al. Structure functional insights into calcium binding during the activation of coagulation factor XIII A. Sci. Rep. 9, 1\u201318 (2019).","journal-title":"Sci. Rep."},{"key":"27359_CR52","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000334157","volume":"33","author":"JJ Sands","year":"2012","unstructured":"Sands, J. J. et al. Effects of citrate acid concentrate (Citrasate\u00ae) on heparin N requirements and Hemodialysis adequacy: A Multicenter, prospective noninferiority trial. Blood Purif. 33, 199\u2013204 (2012).","journal-title":"Blood Purif."},{"key":"27359_CR53","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ekir.2023.11.027","volume":"9","author":"J van der Meulen","year":"2024","unstructured":"van der Meulen, J. Green nephrology: Citrate, the green alternative to heparin in Hemodialysis. Kidney Int. Rep. 9, 191\u2013193 (2024).","journal-title":"Kidney Int. Rep."},{"key":"27359_CR54","unstructured":"Vroman, L., Adams, A. L. & Klings, M. Interactions among human blood proteins at interfaces. Fed. Proc. 30, 1494\u20131502 (1971)."},{"key":"27359_CR55","doi-asserted-by":"publisher","first-page":"179","DOI":"10.14356\/kona.2016024","volume":"33","author":"E Iritani","year":"2016","unstructured":"Iritani, E. & Katagiri, N. Developments of blocking filtration model in membrane filtration. KONA Powder Part. J. 33, 179\u2013202 (2016).","journal-title":"KONA Powder Part. J."},{"key":"27359_CR56","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/S0140-6736(87)90266-2","volume":"329","author":"J Bergstr\u00f6m","year":"1987","unstructured":"Bergstr\u00f6m, J. & Wehle, B. No change in corrected \u03922-Microglobulin concentration after Cuprophane haemodialysis. Lancet 329, 628\u2013629 (1987).","journal-title":"Lancet"},{"key":"27359_CR57","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1093\/ndt\/13.8.2098","volume":"13","author":"C Johner","year":"1998","unstructured":"Johner, C., Chamney, P. W., Schneditz, D. & Kramer, M. Evaluation of an ultrasonic blood volume monitor. Nephrol. Dial Transpl. 13, 2098\u20132103 (1998).","journal-title":"Nephrol. Dial Transpl."},{"key":"27359_CR58","doi-asserted-by":"crossref","unstructured":"Gomez, M., Ba\u00f1on-Maneus, E., Arias-Guill\u00e9n, M. & Maduell, F. Assessment of removal and adsorption enhancement of high-flux hemodialyzers in convective therapies by a novel in vitro uremic matrix. Sci Rep 10, (2020).","DOI":"10.1038\/s41598-020-74528-5"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27359-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27359-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27359-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T13:06:29Z","timestamp":1765285589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27359-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["27359"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-27359-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"F. M. has received consultancy fees and lecture fees from Amgen, Baxter, BBraun, Medtronic, Nipro and expenditure for travel and hospitality and conference fees from Fresenius Medical Care.J.J.B. has received consultancy fees from Kyowa Kirin, NovoNordisk, Bayer, Rubi\u00f3, Esteve, Chiesi, lecture fees from AstraZeneca, Fresenius Medical Care, Diaverum, Bayer, Novartis, NovoNordisk, Boehringer Ingelheim, Lilly, CSL Vifor, Daiichi-Sankyo, a research grant from Kyowa Kirin , and expenditure for travel and hospitalitytraining activities from Fresenius Medical Care, Bayer, and AstraZeneca. All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43437"}}